Operon Discontinues Sale of Arrays in N. America Due to Concerns about Affy Patents

Jun 01, 2001

NEW YORK, June 1 - Qiagen subsidiary Operon said it has discontinued sales of its pre-fabricated, medium-density OpArrays in North America, due to concerns that they might infringe on Affymetrix’s patent portfolio.

Operon attorneys have interpreted Affymetrix’s patents as covering any array with over 60 unique features per square centimeter, while they previously interpreted Affymetrix’s patents as covering any array with over 400 features per square centimeter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Main menu